Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1093 daily bars · split adjusted
Current price $4.58
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 16, 26 | Barclays |
Daily · Wilder smoothing
| Underweight |
| Overweight |
| Mar 24, 26 | UBS | maintain | Buy | Buy |
| Mar 24, 26 | Barclays | maintain | Underweight | Underweight |
| Nov 18, 25 | UBS | maintain | Buy | Buy |
| Nov 4, 25 | Deutsche Bank | downgrade | Buy | Hold |
| Oct 14, 25 | Morgan Stanley | upgrade | Equal Weight | Overweight |
| Sep 23, 25 | Deutsche Bank | upgrade | Hold | Buy |
| Jul 18, 25 | UBS | maintain | Buy | Buy |
| Jul 25, 24 | Barclays | maintain | Overweight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.72 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 4.01 | Oscillator | Buy |
| Williams %R (14) | -99.38 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.14 (Hist -0.13) | Oscillator | Strong Sell |
| Average Directional Index (14) | 23.40 (+DI 21.2 / -DI 30.9) | Trend | Sell |
| EMA 20 | 5.27 | MA | Strong Sell |
| SMA 20 | 5.47 | MA | Strong Sell |
| EMA 50 | 5.10 | MA | Strong Sell |
| SMA 50 | 5.24 | MA | Strong Sell |
| SMA 200 | 4.21 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ALVO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -7.8x | 4.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -341.8x | EPS est. -0.01 | Elevated |
| Price / Book | -8.5x | -4.5x | Elevated |
| Price / Sales | 3.3x | 14.3x | Discount |
| EV / EBITDA | 450.5x | -39.6x | Discount |
| Return on equity | 76.8% | — | Top tier |
| Gross margin | 60.4% | 33.8% | Above hist. |
| Debt / Equity | -7.58 | -2.88 | Conservative |
| Piotroski / Altman Z | 0/9 | Z -1.22 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 20, 2026 | 2026-10-20 08:00:05 | View |
| 6-K | Oct 14, 2026 | 2026-10-14 10:05:07 | View |
| 6-K | Oct 7, 2026 | 2026-10-07 10:16:41 | View |
| 6-K | Oct 5, 2026 | 2026-10-05 07:56:38 | View |
| 6-K | Aug 31, 2026 | 2026-08-31 08:00:07 | View |
| 6-K | Aug 21, 2026 | 2026-08-21 10:37:21 | View |
| 6-K | Aug 19, 2026 | 2026-08-19 16:34:47 | View |
| 6-K | Jul 29, 2026 | 2026-07-29 11:00:05 | View |
| 6-K | Jul 1, 2026 | 2026-07-01 08:00:04 | View |
| SC 13D/A | Jun 30, 2026 | 2026-06-30 20:08:43 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
FY2023 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have assigned a buy recommendation to the
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time.
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
Alvotech (NASDAQ: ALVO - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 19, 2026 | -0.05 | -0.11 | Miss -109.1% | $106.0M |
| May 6, 2026 | -0.07 | -0.09 | Miss -28.6% | $105.9M |
| Mar 18, 2026 | -0.01 | -0.37 | Miss -6334.8% | $173.2M |
| Nov 12, 2025 | -0.03 | -0.02 | Beat 24.9% | $114.0M |
| Aug 13, 2025 | -0.05 | 0.14 | Beat 403.4% | $173.3M |
| May 7, 2025 | -0.08 | 0.35 | Beat 537.5% | $132.8M |